Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 586 citations

Medicine, Oncology, Pharmacology +11

A dimerization-dependent mechanism drives RAF catalytic activation

Thanashan Rajakulendran, Malha Sahmi, Martin Lefrançois et al. · Nature · 2009 · 498 citations

Life Sciences, Biochemistry, Molecular Biology +3

RAF inhibitors that evade paradoxical MAPK pathway activation

Chao Zhang, Wayne Spevak, Ying Zhang et al. · Nature · 2015 · 381 citations

Life Sciences, Cancer Biology, Oncology +14

Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors

Piro Lito, Anna Saborowski, Jingyin Yue et al. · Cancer Cell · 2014 · 312 citations · Full text

Medicine, Cancer Biology, Oncology +14

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Sheng-Bin Peng, James R. Henry, Michael D. Kaufman et al. · Cancer Cell · 2015 · 309 citations · Full text

Medicine, Cancer Biology, Oncology +16